- ImmunoGen (NASDAQ:IMGN +0.5%) FQ2 results: Revenues: $48.3M (+60.5%); R&D Expense: $27.6M (+32.1%); G&A: $6.9M (+27.8%); Operating Income: $13.8M (+263.2%); Net Income: $13.6M (+257.9%); EPS: $0.16 (+300.0%); Quick Assets: $106.6M (-25.1%); CF Ops: $34.4M (+59.3%).
- 2015 Guidance: Revenues: $100M - 105M; operating expenses: $160M - 165M; net loss: ($60M - 65M); cash burn: ($55M - 60M); capex: $7M - 9M; quick assets at fiscal year end: $75M - 85M. All items unchanged from FQ1 guidance.